Valuation
- Market cap
- 11,075,000
- Revenue TTM
- $0
- Net income TTM
- $-37,430,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.08
Trading
- Volume
- 370,063
- Avg volume
- 383,696
- Day's range
- $0.39 – $0.47
- Shares out
- 27,453,000
- Stochastic %K
- 26%
- Beta
- 1.00
- Analysts
- Sell
- Price target
- $4.00
Company profile
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroi...
Show more
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 908 967 6677
- Website
- https://citiuspharma.com
- Address
- 11 Commerce Drive, First Floor, Cranford, United States
Latest news
No headlines yet.
